See the DrugPatentWatch profile for azacitidine

Azacitidine is a medication used to treat certain types of blood cancers, such as myelodysplastic syndromes and acute myeloid leukemia. Ruxolitinib, on the other hand, is a drug used to treat bone marrow disorders, including myelofibrosis and polycythemia vera.

According to a study published in the American Journal of Hematology, the combination of azacitidine and ruxolitinib may have a synergistic effect in treating myelofibrosis, a type of bone marrow disorder. The study found that the combination of the two drugs led to a higher response rate compared to using either drug alone. Additionally, the study found that the combination therapy was well-tolerated, with few adverse effects.

It is important to note that while the study suggests a potential benefit to using the two drugs together, further research is needed to fully understand the impact of azacitidine on ruxolitinib's effectiveness.

Another source, DrugPatentWatch.com, reports that both azacitidine and ruxolitinib are currently approved by the FDA for the treatment of various blood cancers and disorders. However, DrugPatentWatch.com does not provide information on the impact of azacitidine on ruxolitinib's effectiveness.

In summary, a study published in the American Journal of Hematology suggests that the combination of azacitidine and ruxolitinib may have a synergistic effect in treating myelofibrosis. However, further research is needed to fully understand the impact of azacitidine on ruxolitinib's effectiveness.

Sources:

* American Journal of Hematology: <https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25633>
* DrugPatentWatch.com: <https://www.drugpatentwatch.com/drugs/azacitidine.html>, <https://www.drugpatentwatch.com/drugs/ruxolitinib.html>